Exelixis

YTD

ALL

Trade Exelixis 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About EXEL

Exelixis, Inc. is an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic.

CEO

Michael M. Morrissey

CEOMichael M. Morrissey

Employees

1,077

Employees1,077

Headquarters

Alameda, California

HeadquartersAlameda, California

Founded

1994

Founded1994

Employees

1,077

Employees1,077

EXEL Key Statistics

Market cap

13.41B

Market cap13.41B

Price-Earnings ratio

17.52

Price-Earnings ratio17.52

Dividend yield

—

Dividend yield—

Average volume

2.78M

Average volume2.78M

High today

$53.70

High today$53.70

Low today

$50.89

Low today$50.89

Open price

$52.72

Open price$52.72

Volume

1.14M

Volume1.14M

52 Week high

$53.93

52 Week high$53.93

52 Week low

$33.76

52 Week low$33.76

Stock Snapshot

The current Exelixis(EXEL) stock price is $53.35, with a market capitalization of 13.41B. The stock trades at a price-to-earnings (P/E) ratio of 17.52.

During the trading session on 2026-06-25, Exelixis(EXEL) shares reached a daily high of $53.70 and a low of $50.89. At a current price of $53.35, the stock is +4.8% higher than the low and still -0.7% under the high.

Trading volume for Exelixis(EXEL) stock has reached 1.14M, versus its average volume of 2.78M.

Over the past 52 weeks, Exelixis(EXEL) stock has traded between a high of $53.93 and a low of $33.76.

EXEL News

Investing.com 6h

Truist assumes Exelixis stock coverage with Hold rating on pipeline uncertainty - Investing.com

...

TipRanks 8h

Exelixis assumed with Hold from Buy at Truist

Truist analyst Gregory Renza downgraded Exelixis (EXEL) to Hold from Buy with a price target of $54, up from $51, after assuming coverage of the name. The compa...

Simply Wall St 10h

Does STELLAR-303’s Mixed Survival Signal Reshape the Bull Case for Exelixis’ Pipeline Strategy?

Exelixis recently reported final overall survival results from the phase 3 STELLAR-303 trial, showing a non-statistically significant trend favoring zanzalintin...

Analyst ratings

50%

of 20 ratings

Buy

40%

Hold

50%

Sell

10%

More EXEL News

TipRanks 2d

Exelixis Colorectal Cancer Data Underwhelms: Gerberry Maintains Sell/Underperform with Price Target Below Current Share Price

Exelixis, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason Gerberry from Bank of America Securities maintained a S...

Benzinga 3d

Exelixis Provides 'A Highly Defensive Investment Profile:' Analyst

EExelixis Inc. NASDAQ: EXEL) on Monday reported final overall survival data from the Phase 3 STELLAR-303 trial. The data showed that the investigational combin...

People also own

Based on the portfolios of people who own EXEL. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.